Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
Public ClinicalTrials.gov record NCT02242643. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' quadrivalent influenza vaccine (GSK2282512A) compared to Sanofi Pasteur's Fluzone® Quadrivalent in children 6 to 35 months of age.
Study identification
- NCT ID
- NCT02242643
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,432 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Months to 35 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2014
- Primary completion
- Mar 15, 2015
- Completion
- Jun 22, 2015
- Last update posted
- Sep 6, 2018
2014 – 2015
United States locations
- U.S. sites
- 64
- U.S. states
- 26
- U.S. cities
- 59
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35235 | — |
| GSK Investigational Site | Dothan | Alabama | 36305 | — |
| GSK Investigational Site | Tucson | Arizona | 85741 | — |
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | Anaheim | California | 92804 | — |
| GSK Investigational Site | Chino | California | 91710 | — |
| GSK Investigational Site | Daly City | California | 94015 | — |
| GSK Investigational Site | Fresno | California | 93726 | — |
| GSK Investigational Site | Hayward | California | 94545 | — |
| GSK Investigational Site | Oakland | California | 94611 | — |
| GSK Investigational Site | Paramount | California | 90723 | — |
| GSK Investigational Site | Pleasanton | California | 94588 | — |
| GSK Investigational Site | Sacramento | California | 95815 | — |
| GSK Investigational Site | Sacramento | California | 95822 | — |
| GSK Investigational Site | Sacramento | California | 95823 | — |
| GSK Investigational Site | Santa Clara | California | 95051 | — |
| GSK Investigational Site | Walnut Creek | California | 94596 | — |
| GSK Investigational Site | West Covina | California | 91790 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80920 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80922 | — |
| GSK Investigational Site | Lake Mary | Florida | 32736 | — |
| GSK Investigational Site | Miami Lakes | Florida | 33014 | — |
| GSK Investigational Site | Nampa | Idaho | 83686 | — |
| GSK Investigational Site | Augusta | Kansas | 67010 | — |
| GSK Investigational Site | Newton | Kansas | 67114 | — |
| GSK Investigational Site | Topeka | Kansas | 66604 | — |
| GSK Investigational Site | Wichita | Kansas | 67207 | — |
| GSK Investigational Site | Louisville | Kentucky | 40291 | — |
| GSK Investigational Site | Bossier City | Louisiana | 71111 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006 | — |
| GSK Investigational Site | Columbia | Maryland | 21045 | — |
| GSK Investigational Site | Woburn | Massachusetts | 01801 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68504 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68505 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68516 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89104 | — |
| GSK Investigational Site | Binghamton | New York | 13901 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27609 | — |
| GSK Investigational Site | Beavercreek | Ohio | 45431 | — |
| GSK Investigational Site | Cleveland | Ohio | 44121 | — |
| GSK Investigational Site | Dayton | Ohio | 45406 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16505 | — |
| GSK Investigational Site | Hermitage | Pennsylvania | 16148 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| GSK Investigational Site | Sellersville | Pennsylvania | 18960 | — |
| GSK Investigational Site | Charleston | South Carolina | 29406 | — |
| GSK Investigational Site | Cheraw | South Carolina | 29520 | — |
| GSK Investigational Site | Kingsport | Tennessee | 37660 | — |
| GSK Investigational Site | Austin | Texas | 78705 | — |
| GSK Investigational Site | Fort Worth | Texas | 76135 | — |
| GSK Investigational Site | Galveston | Texas | 77555-1119 | — |
| GSK Investigational Site | Tomball | Texas | 77375 | — |
| GSK Investigational Site | Layton | Utah | 84041 | — |
| GSK Investigational Site | Orem | Utah | 84057 | — |
| GSK Investigational Site | Payson | Utah | 84651 | — |
| GSK Investigational Site | Provo | Utah | 84604 | — |
| GSK Investigational Site | Roy | Utah | 84067 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84124 | — |
| GSK Investigational Site | South Jordan | Utah | 84095 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22902 | — |
| GSK Investigational Site | Ellensburg | Washington | 98926 | — |
| GSK Investigational Site | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02242643, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 6, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02242643 live on ClinicalTrials.gov.